CN1569197A - Chinese medicinal soft capsule and preparing process thereof - Google Patents
Chinese medicinal soft capsule and preparing process thereof Download PDFInfo
- Publication number
- CN1569197A CN1569197A CNA2004100374097A CN200410037409A CN1569197A CN 1569197 A CN1569197 A CN 1569197A CN A2004100374097 A CNA2004100374097 A CN A2004100374097A CN 200410037409 A CN200410037409 A CN 200410037409A CN 1569197 A CN1569197 A CN 1569197A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- weight portion
- semen strychni
- soft capsule
- mesh sieves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 71
- 238000002360 preparation method Methods 0.000 claims abstract description 38
- 210000000582 semen Anatomy 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000005325 percolation Methods 0.000 claims description 20
- 238000001556 precipitation Methods 0.000 claims description 15
- 238000011084 recovery Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 238000000227 grinding Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 238000007670 refining Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000007872 degassing Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 201000002282 venous insufficiency Diseases 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 2
- 241001092084 Agrimonia Species 0.000 claims 2
- 235000016993 Agrimonia Nutrition 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 abstract description 4
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 38
- 230000000694 effects Effects 0.000 description 25
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 19
- 241001279009 Strychnos toxifera Species 0.000 description 19
- 229960005453 strychnine Drugs 0.000 description 19
- 238000000605 extraction Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000008030 elimination Effects 0.000 description 9
- 238000003379 elimination reaction Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 240000002853 Nelumbo nucifera Species 0.000 description 7
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 7
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000007963 capsule composition Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- NQGCBDWQKDAGTK-RYZVSIALSA-N Agrimophol Chemical compound CC1=C(OC)C(C(=O)CCC)=C(O)C(C[C@]2(C)C(C(C(=O)[C@H](C)CC)=C(O)C(C)=C2O)=O)=C1O NQGCBDWQKDAGTK-RYZVSIALSA-N 0.000 description 3
- NQGCBDWQKDAGTK-QDXKXIGTSA-N Agrimophol Natural products O=C(CCC)c1c(OC)c(C)c(O)c(C[C@]2(C)C(=O)C(C(=O)[C@H](CC)C)=C(O)C(C)=C2O)c1O NQGCBDWQKDAGTK-QDXKXIGTSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- TYFJTEPDESMEHE-HNNXBMFYSA-N (3s)-6,8-dihydroxy-3-[2-(4-methoxyphenyl)ethyl]-3,4-dihydroisochromen-1-one Chemical compound C1=CC(OC)=CC=C1CC[C@@H]1OC(=O)C2=C(O)C=C(O)C=C2C1 TYFJTEPDESMEHE-HNNXBMFYSA-N 0.000 description 2
- ALLQLKDRPRORFM-UHFFFAOYSA-N 1-[3,5-bis[[2,6-dihydroxy-4-methoxy-3-methyl-5-(2-methylpropanoyl)phenyl]methyl]-2,4,6-trihydroxyphenyl]-2-methylbutan-1-one Chemical compound CCC(C)C(=O)c1c(O)c(Cc2c(O)c(C)c(OC)c(C(=O)C(C)C)c2O)c(O)c(Cc2c(O)c(C)c(OC)c(C(=O)C(C)C)c2O)c1O ALLQLKDRPRORFM-UHFFFAOYSA-N 0.000 description 2
- TYFJTEPDESMEHE-UHFFFAOYSA-N agrimonolide Natural products C1=CC(OC)=CC=C1CCC1OC(=O)C2=C(O)C=C(O)C=C2C1 TYFJTEPDESMEHE-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- ZTHVHELPCLGXHF-JPPAUQSISA-N beta-colubrine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C1=CC=C(C=C11)OC)CC=C2CN2[C@@H]3[C@]41CC2 ZTHVHELPCLGXHF-JPPAUQSISA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000001034 respiratory center Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007560 sedimentation technique Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001113846 Loganiaceae Species 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- POLBLONFVZXVPI-UHFFFAOYSA-N N-methyl-sec-pseudobrucine Natural products O=C1CC2C3C(CC4=O)OCC=C2CN(C)CCC11C3N4C2=C1C=C(OC)C(OC)=C2 POLBLONFVZXVPI-UHFFFAOYSA-N 0.000 description 1
- WJHSRFQBVYHKKL-UHFFFAOYSA-N Oroboside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(C=3C=C(O)C(O)=CC=3)=COC2=C1 WJHSRFQBVYHKKL-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- FQYUMYWMJTYZTK-UHFFFAOYSA-N Phenyl glycidyl ether Chemical compound C1OC1COC1=CC=CC=C1 FQYUMYWMJTYZTK-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- ZMTYENXGROJCEA-LNKPQSDASA-N Vomicine Chemical compound O1CC=C([C@@H]2CC3=O)CN(C)CC[C@]43C(C=CC=C3O)=C3N3C(=O)C[C@H]1[C@H]2[C@H]34 ZMTYENXGROJCEA-LNKPQSDASA-N 0.000 description 1
- WKECTJXZMZMDBI-UHFFFAOYSA-N Vomicine Natural products Oc1cccc2c1N3C4C5C(CC3=O)OCC=C6CNCCC24C(=O)CC56 WKECTJXZMZMDBI-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- POLBLONFVZXVPI-SVFVWZOVSA-N novacine Chemical compound O([C@@H](CC1=O)[C@@H]2[C@H]3CC4=O)CC=C3CN(C)CC[C@]43[C@H]2N1C1=C3C=C(OC)C(OC)=C1 POLBLONFVZXVPI-SVFVWZOVSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000012065 two one-sided test Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Abstract
The invention provides a Chinese medicinal soft capsule for suppressing tumor growth and its preparation, wherein the soft capsule is prepared from curcuma aromatica, hairy vein agrimony, bitter orange as raw material through ethanol backflow and spray-drying.
Description
Technical field
The present invention relates to a kind of soft capsule preparation and preparation method thereof, particularly relate to pure Chinese medicinal soft capsule preparation of a kind of blood circulation promoting and blood stasis dispelling, pain-relieving powder for treating joint, heat-clearing and toxic substances removing, strengthening vital QI to eliminate pathogenic factors, inhibition tumor growth, human body immunity improving power and preparation method thereof, belong to medical technical field.
Background technology
Clinically for tumor treatment as a rule based on the method for operation, chemotherapy and operation combined chemotherapy, treatment meanss such as radiotherapy, enhancing human body immunity power are auxilliary.But above-mentioned Therapeutic Method all has bigger untoward reaction usually, and as the gastrointestinal reaction, passive protective physical fitness descends or the like behind alopecia, leukopenia, postoperative or the radiation exposure.PINGXIAO JIA0NANG is the pharmaceutical preparation with strengthening vital QI to eliminate pathogenic factors, enhancing human body immunity power, inhibition tumor growth of being made by pure Chinese medicines such as Radix Curcumae, Herba Agrimoniae, Fructus Aurantii, Semen Strychni Pulveratums.Verify by clinical the use widely, prove that its antitumor curative effect is definite, can effectively improve patient's immune level (cellular immunization, humoral immunization) and with chemotherapeutics treatment, radiotherapy and use, effect with attenuation synergistic, can alleviate clinical symptoms, stablize the state of an illness, reduce relapse rate, on the basis of improving life quality, the effect that effectively prolongs life cycle.But existing clinically oral formulations is tablet and hard capsule, and it is poor to exist oral absorption, and bioavailability is low, and easily the moisture absorption is not easy to carry, and the diversity of tabletting or filling is bigger aborning, is subjected to many shortcomings such as secondary pollution easily.In addition, the more important thing is each dose patient's every day big (can reach 24 every day at most).Because contain Semen Strychni Pulveratum in the prescription, and Semen Strychni is a kind of therapeutic dose and the more approaching toxic medicament of toxic dose, have another name called bitter reality, vomiting nut, Semen Strychni, be the seed of loganiaceae plant Semen Strychni.Cold in nature, bitter in the mouth is poisonous.Return liver, spleen channel.Effect mass dissipating and swelling eliminating, removing obstruction in the collateral to relieve pain, tradition are used for rheumatoid arthritis stubborn, paralysis and numbness, cellulitis carbuncle and painful swelling, traumatic injury etc.Say Semen Strychni " open meridians, the merit that reaches the joint thoroughly outclass its medicine " in " Records of Tradition Chinese and Western Medicine in Combination ".Semen Strychni clinical practice nearly one thousand years do not wane, and illustrate that it has significant effect, are " severe and lingering illness has been apt in the violent agent of poison ".Successive dynasties have been experienced from " nontoxic " to " poisonous " process to " big poison " to the toxic understanding of Semen Strychni.Modern pharmacological research shows that Semen Strychni contains brucine (strychnine), strychnine (Bu Lusheng), γ-colubrine and β-colubrine, vomicine, novacine, loganin etc.Main alkaloid is strychnine and strychnine.The reflection function of the at first excited spinal cord of therapeutic dose, respiratory center and vasomotor center in next excited oblongata, and can improve the sensorial function of cerebral cortex.Toxic dose can suppress respiratory center.Strychnine can also strengthen the effect that stops cholinesterase to destroy acetylcholine, and enterokinesia is strengthened, and causes stomachache, diarrhoea.Neural intramuscular all capable of blocking passes when strychnine and strychnine maximal dose, presents curariform action mask.Semen Strychni also can directly damage renal cells, causes acute renal failure, uremia.Oral strychnine 1 time can be poisoned for 5～10 milligrams, and 30 milligrams can cause death and die; Clothes Semen Strychni crude drug 7 grams can cause death and die.Latent period of poisoning is 30～180 minutes.Therefore " the medical toxicant management method " of Ministry of Public Health issue stipulates that clearly this class medicine of similar strychnine should strict control and management.Contain strychnine in every of the PINGXIAO JIA0NANG and can reach 0.35mg at most, according to taking 24 of every days, then the strychnine consumption can reach 8.4mg/ day, with maximum dose 10mg on the one of strychnine very near (strychnine maximum dose on the one is 10mg in the kind of poisonous substances (Ministry of Public Health is defended No. 27 file of medicine (89) " about carrying out the notice of " medical toxicant management method " ")).Therefore, if can effectively improve bioavailability, reduce the content of strychnine in the preparation and dose every day of preparation, just can be more economically, the effect of the flat oral preparation for eliminating blood circulation promoting and blood stasis dispelling of performance of safety, pain-relieving powder for treating joint, inhibition tumor growth, strengthening vital QI to eliminate pathogenic factors, human body immunity improving power.
In addition,, can reduce each dose so on the one hand, also can increase bioavailability on the other hand, better be absorbed by human body if can make with extra care extraction by the other side's Chinese medicine.
Summary of the invention
The purpose of this invention is to provide a kind of pure Chinese medicinal soft capsule preparation; Second purpose of the present invention provides a kind of bioavailability height, safe refining pure Chinese medicinal soft capsule preparation; The 3rd purpose of the present invention provides a kind of preparation method of Chinese medicinal soft capsule preparation; Another object of the present invention provides a kind of preparation method that can make with extra care the Chinese medicinal soft capsule preparation that extracts to crude drug.
For achieving the above object, the present invention has adopted following technical scheme:
Radix Curcumae 50～58 weight portions; Herba Agrimoniae 50～58 weight portions; Fructus Aurantii 85～95 weight portions; Oletum Trogopterori 40～50 weight portions; Alumen 50～58 weight portions; Sal Nitri 50～58 weight portions; Resina Toxicodendri 15～20 weight portions; Semen Strychni Pulveratum 15～30 weight portions.
More than eight the flavor medicines adopt following preparation method can make soft capsule preparation of the present invention.Concrete process program is as follows:
Process program:
1. extract:
(1) with Radix Curcumae, Fructus Aurantii two flavor pulverizing medicinal materials become coarse powder, cross 24 orders～50 mesh sieves; Oletum Trogopterori, Alumen, Sal Nitri, Resina Toxicodendri four Chinese medicine material is ground into fine powder, crosses 100 orders～120 mesh sieves; Use the 60-80% ethanol percolation, merge behind the diacolation liquid recycling ethanol;
(2) the last medicinal residues of percolation are with Herba Agrimoniae decocting three times, and collecting decoction filters, and concentrates; Add ethanol and staticly settle, the collecting precipitation thing is dissolved in water;
(3) percolate spherical tank decompression recycling ethanol is crossed the macropore resin bed respectively after merging and pure hypostasis filter with 400 order filter clothes behind the percolate recovery ethanol and is analysed post, with ethanol and distilled water eluting; Obtain refining extract after the concentrated back of merging eluent is spray-dried;
2. add in the above-mentioned refining extract and cross 80～120 mesh sieves through the Semen Strychni Pulveratum mix homogeneously of superfine grinding, under stirring, join solvent gradually, heating makes it to remain on 40～80 ℃ and stir and to make it dissolving, the dissolving back adds adjuvants such as wetting agent, suspending agent and stabilizing agent, fully stirring makes it be mixed into uniform suspension, again suspension crossed pelleting behind colloid mill, the degassing evacuation, finalized the design, select ball, wash ball, drying, promptly.
The described solvent of above-mentioned preparation method can be any one or any several mixture in vegetable oil, PEG400, PGE, isopropyl alcohol, glycerol, tween 80, the water etc.; Adjuvant such as stabilizing agent, suspending agent can be any one or a few the mixture in glycerol, water, soybean lecithin, Cera Flava, aluminum monostearate, ethyl cellulose, the solid polyethylene glycol etc.
Through investigating, test Semen Strychni pharmacokinetic parameter in vivo and analyzing and learn, Semen Strychni Pulveratum is used as medicine after superfine grinding is impalpable powder, can accelerate, strengthen its absorption in vivo, also can accelerate simultaneously its removing in vivo, reduce accumulating in vivo.Therefore,, the consumption of Semen Strychni be can reduce, same even better therapeutic reached being used as medicine after the Semen Strychni Pulveratum superfine grinding, and littler to the toxic and side effects of body.In addition, the extractum of eight flavor medicines is pulverized the back to be dissolved as solvent dispersion with vegetable oil, simultaneously can add surfactant or other absorption enhancers, oil phase was because of the effect of surfactant after medicine entered in the body, can spontaneous formation Emulsion, drug powder distributes between oil/water is biphase on the one hand, relies on the huge surface area of little oil droplet to be distributed in rapidly and uniformly in the gastrointestinal tract, increases effective absorbing area; The chyle of Xing Chenging can enter blood through lymphsystem on the other hand, has avoided the influence of first pass effect, so bioavailability of medicament can be greatly improved.
Adopt decoction and alcohol sedimentation technique to extract among the present invention simultaneously, the more abundant reservation, effectively pressed down the cancer medicinal ingredient in the Herba Agrimoniae, therefore can improve the antitumor action of soft capsule preparation of the present invention greatly, and can remove impurity, make effective ingredient of the present invention more definite, improve the curative effect of product of the present invention.
Following experimental example is used to further specify the present invention:
Experimental example 1 soft capsule preparation preparation technology project study of the present invention
The principal agent Herba Agrimoniae has certain antineoplastic action according to its decocting liquid of modern pharmacological research in the prescription.Herba Agrimoniae mainly contains agrimophol (agrimophol), agrimonolide (agrimonolide), and contain galuteolin (luteoloside), Herba Agrimoniae first, second, third element (agrimonin A, B, C), (agrimol A～E), other contains tannin, sterol, Saponin and volatile oil to match agrimophol A～E.The present invention test shows that therefore effect that its water extract-alcohol precipitation extract suppresses tumor obviously greater than n-butanol extract, consider in the extraction process design that extracting Herba Agrimoniae with decoction and alcohol sedimentation technique effectively presses down the cancer medicinal ingredient.
Making with extra care of extract considers to use the macroporous resin chromatographic column to remove impurity such as tannin, starch, phytoprotein.
1. percolation extraction conditions screening
Use orthogonal experiment, investigate factors such as solvent consumption, percolation speed, grinding particle size,, select with experimental establishment research as follows about factor level to the influence of percolation extraction effect:
(1) factor level is selected to learn according to long-term practice, the performance that Chinese medicine leaches the preparation curative effect depends primarily on extraction, and the percolation effect is subjected to the factors such as solvent concentration, dip time, solvent consumption, percolation speed, grinding particle size and the influence of factor varying level.Need dipping a period of time as percolation is last, dip time is defined as 24 hours according to knowhow, so percolation extracts when investigating, and chooses concentration of alcohol, solvent consumption, percolation speed, grinding particle size as factor, the varying level of high spot reviews factor is to the influence of percolation extraction effect.Take all factors into consideration in conjunction with aspects such as production cost, the energy.
(2) index determines that selecting the extractum recovery rate is evaluation index, and its reason and assay method are as follows:
The extractum recovery rate: extractum is the material base of solid preparation performance curative effect, and its recovery rate height directly influences preparation process, is reasonable, effective control device so be chosen as the extraction index.
Assay method: merge extractive liquid,, filter, be adjusted to 1000ml, therefrom get 100ml again, in the dry evaporating dish of having weighed of impouring, water-bath is concentrated into dried, moves into 105 ℃ of oven dryings 3 hours to constant weight, taking-up, put in the exsiccator and cool off after 30 minutes, taking-up is weighed, and calculates.
(3) orthogonal test learns that according to test arrangement and result and The results of analysis of variance best percolation process program is a Radix Curcumae, and Fructus Aurantii two flavor pulverizing medicinal materials become coarse powder, cross 24 mesh sieves; Oletum Trogopterori, Alumen, Sal Nitri, Resina Toxicodendri four Chinese medicine material is ground into fine powder, crosses 100 mesh sieves; With 8 times of amount 70% ethanol, flood after 24 hours, promptly get percolate with 5ml/min speed percolation.
(4) repeated confirmatory experiment carries out repeated confirmatory experiment by above extraction process condition, extracting as a result by visible this optimum organization condition of the result of repeated confirmatory experiment, the extractum yield fluctuates less, all meet the orthogonal test optimum level, as seen this extraction process condition is reasonable, feasible and stable.
2. water extract-alcohol precipitation extraction conditions screening
Use orthogonal experiment, investigate of the influence of factors such as amount of water, decocting time, number of times, alcohol precipitation concentration, precipitate with ethanol time and number of times, select with experimental establishment research as follows about factor level to the water extract-alcohol precipitation extraction effect:
(1) factor level is selected to learn according to long-term practice, the performance that Chinese medicine leaches the preparation curative effect depends primarily on extraction, and extraction effect is subjected to the factors such as amount of water, decocting time, number of times, alcohol precipitation concentration, precipitate with ethanol time and number of times and the influence of factor varying level.So water extract-alcohol precipitation extracts when investigating, and chooses factors such as amount of water, decocting time, number of times, alcohol precipitation concentration, precipitate with ethanol time and number of times, the varying level of high spot reviews factor is to the influence of extraction effect.Take all factors into consideration in conjunction with aspects such as production cost, the energy.
(2) index determines that selecting the extractum recovery rate is evaluation index, and its reason and assay method are as follows:
The extractum recovery rate: extractum is the material base of solid preparation performance curative effect, and its recovery rate height directly influences preparation process, is reasonable, effective control device so be chosen as the extraction index.
Assay method: merge extractive liquid,, filter, be adjusted to 1000ml, therefrom get 100ml again, in the dry evaporating dish of having weighed of impouring, water-bath is concentrated into dried, moves into 105 ℃ of oven dryings 3 hours to constant weight, taking-up, put in the exsiccator and cool off after 30 minutes, taking-up is weighed, and calculates.
(3) orthogonal test learns that best water extract-alcohol precipitation extraction process scheme is that the last medicinal residues of percolation add 8 times of decoctings three times with Herba Agrimoniae, each 2 hours according to test arrangement and result and The results of analysis of variance.Add ethanol and adjust to that to contain the alcohol amount be 80%, 4 ℃～8 ℃ precipitations once, the sedimentation time is 24 hours.
(4) repeated confirmatory experiment carries out repeated confirmatory experiment by above extraction process condition, extracting as a result by visible this optimum organization condition of the result of repeated confirmatory experiment, the extractum yield fluctuates less, all meet the orthogonal test optimum level, as seen this extraction process condition is reasonable, feasible and stable.
3. content is prepared and Study on Forming
(1) specification determines
We investigate the extract powder recovery rate of 3 batches of medical materials, the results are shown in Table 1
Table 1 extract powder recovery rate
The average recovery rate of lot number extract powder recovery rate (%) extract powder (%)
030301 25.2
030302 25.6 25.5
030303 25.7
Be about 25.5% through this technology of test of many times extract powder recovery rate.Making things convenient for the aspect to consider from soft capsule practical condition and taking, the 0.5g extract powder is made 2 soft capsules, is 1: 1 o'clock according to a large amount of evidence extract powders with solvent and adjuvant ratio, and soft capsule content flowability and stability are all relatively good; So soft capsule specification of the present invention is every heavy 0.5g.
(2) prescription determines
The soft capsule preparation technical study is mainly investigated problems such as the mobile and stability, disintegration of the selection of adjuvant and consumption, content.Research contents is as follows:
We select soybean oil, PEG400 respectively for use is substrate, by different proportion extract powder is suspended in wherein, content flowability, stability, disintegration to be index investigation said preparation prescription.The results are shown in Table 2.
Table 2 soft capsule prescription screening of the present invention table
Prescription R1 R2 R3 R4 R5 R6
Extract powder (g) 100 100 100 100 100 100
Auxilliary soybean oil (g) 100 150 200
Material PEG400 (g) 200 150 100
Content is mobile relatively poor better
Investigation refers to
Stability can not have precipitation to have a little precipitation of precipitation relatively poor better by suspendible
Mark
Disintegration (minute) 25.3 15.5 23.5 14.6 22.1 12.9
Annotate: above prescription is and earlier extract powder is added in the adjuvant (soybean oil or PEG400), and low speed stirs diffusing, and then the speed of speedup to 400 rev/min stirred 1.5 hours gradually, suspendible evenly back is crossed colloid mill, be pressed into soft capsule, clean drying with 95% ethanol.
The content flowability is judged the content flowability according to knowhow.
After stability leaves standstill 48 hours with the content for preparing, get the sample determination (liquid is divided into upper, middle and lower-ranking) of different liquid layers, measure strychnine content wherein, to investigate the stability of content.
Be medium disintegration with the simulated gastric fluid, under 37 ± 1 ℃ of conditions, according to an appendix VII of Chinese Pharmacopoeia version in 2000 A inspection technique disintegration, measures in accordance with the law.
Conclusion:, think the better and requirement up to specification of prescription R6 to be suitable for big production through integrated survey to content flowability, stability and soft capsule disintegration; So select the R6 prescription for use.
(3) preparation of rubber solution
The elasticity size of soft capsule shell depends on the weight ratio between dry gelatin in the softgel shell, plasticizer (often being glycerol, sorbitol or both mixture) and the water three.Through investigate finding that relatively relatively the weight ratio of Shi Heing is dried plasticizer: dry gelatin=0.4～0.6: 1.0, and the ratio of water and gelatin is about 1: 1.2.The consistency and elasticity of the softgel shell under this ratio is all proper.Determine that through comparative test three's proper ratio is a gelatin: water: glycerol=1: 0.9: 0.5.
Gelatin, water, glycerol are put into container according to the above ratio, be heated to about 80 ℃, add an amount of screening agent (as food coloring), correctives (as sucrose, xylitol), antiseptic (as methyl parahydroxybenzoate, propyl p-hydroxybenzoate etc.) stirring again, make fully and dissolve, be incubated 1～2 hour, leave standstill, make the foam come-up, defoam, filter, 60 ℃ of insulations promptly get rubber solution.Experimental example 2: the pharmacokinetics comparative study of thick Semen Strychni Pulveratum and ultra-fine Semen Strychni Pulveratum
Get 200 of mices, divide 20 groups at random, each 10 groups of thick Semen Strychni Pulveratum and ultra-fine Semen Strychni Pulveratum test group compare test and investigate thick Semen Strychni Pulveratum and ultra-fine Semen Strychni Pulveratum absorption process different in vivo.Each organizes mice respectively with the disposable administration of single dose.After the administration, serve as to detect index, be determined at the blood drug level of strychnine in the different intervals point mouse blood with the HPLC method with strychnine in the Semen Strychni.The result shows that the Semen Strychni absorption in vivo meets one compartment open model, and the main pharmacokinetic parameters of thick Semen Strychni Pulveratum is: T
Max=0.34h, C
Max=2.36 μ gmL
-1, AUC=32.59 μ gmL
-1H
-1, CL=2.79 μ gmL
-1H
-1The main pharmacokinetic parameters of ultra-fine Semen Strychni Pulveratum is: T
Max=0.36h, C
Max=4.53ngmL
-1, AUC=9.76 μ gmL
-1, CL=9.26ngmL
-1H
-1
Above-mentioned thick Semen Strychni Pulveratum and thin Semen Strychni Pulveratum storage and time relationship in animal body sees Table 3 and table 4.
The body storage and the time relationship of the thick Semen Strychni Pulveratum of table 3
Mortality rate body storage in the time of at interval
Group number of animals death toll
Between/h/%/mgkg-1
1 0.25 10 9 0.90 159.66
2 0.5 10 8 0.80 131.36
3 1 10 9 0.90 157.23
4 2 10 7 0.70 123.52
5 3 10 7 0.70 123.52
6 4 10 6 0.60 107.63
7 6 10 4 0.40 77.94
8 8 10 3 0.30 64.72
9 12 10 2 0.20 51.25
10 14 10 1 0.10 28.79
The body storage and the time relation of the ultra-fine Semen Strychni Pulveratum of table 4
Number of animals death toll mortality rate body storage during the group interval
Between/h/%/mgkg-1
1 0.25 10 10 1.00 182.47
2 0.5 10 9 0.90 151.33
3 1 10 9 0.95 179.25
4 2 10 8 0.80 118.69
5 3 10 5 0.50 68.51
6 4 10 6 0.60 79.82
7 6 10 3 0.30 31.58
8 8 10 2 0.20 23.27
9 12 10 1 0.10 11.47
10 14 10 0 0.00 9.82
Result of the test shows that its absorption in vivo can be accelerated, be strengthened to Semen Strychni after superfine grinding, and its oral back toxic action also has increase to a certain degree simultaneously; But Semen Strychni can quicken its elimination in vivo again through superfine grinding on the other hand, reduces its accumulating in vivo.Semen Strychni Pulveratum decrement after superfine grinding can be used as medicine clinically can reach and the same curative effect of former dosage coarse powder, and can excrete faster, reduces noxious substance accumulating in vivo.
Experimental example 3: the comparison (bioequivalence test) of the capsule of soft capsule preparation of the present invention and same recipe aspect bioavailability
Get 10 of the beagle dogs of growing up, divide 2 groups at random, each 1 group of soft capsule dosage form of the present invention and capsule formulation test group compare test and investigate soft capsule dosage form of the present invention and capsule formulation absorption process different in vivo.Each organizes the beagle dog respectively with 10 times of disposable administrations of clinical using dosage (soft capsule 0.25g/ grain of the present invention * 20, capsule 0.21g/ grain * 40) after the administration, with strychnine in the preparation serves as to detect index, is determined at the blood drug level of strychnine in the different time points beagle dog blood with the HPLC method.Area (AUC under blood drug level-time graph
0-t) calculate blood peak concentration of drug (C with trapezoidal method
Max) and peak time (T
Max) directly obtain by test data, adopt two-one sided test, the AUC of soft capsule dosage form of the present invention and capsule formulation is carried out evaluation of bioequivalence, eliminate half-life (T
1/2) adopt the 3P87 medicine to calculate for process simulation.
Two kinds of drug form dynamic metabolism parameters relatively see Table 5 and 6.
The pharmacokinetic parameter of table 5 soft capsule dosage form of the present invention
The numbering maximum plasma concentration reaches the dense half-life (T in blood medicine peak
1/2) area under curve (AUC
0-t1/2)
(C
MAX) μ g/ml spends time H μ g/ml*H
(T
MAX)H
1 5.36 0.34 3.29 12.261
2 5.28 0.36 3.18 11.167
3 5.68 0.34 3.23 12.311
4 5.25 0.38 3.21 11.143
5 5.72 0.36 3.24 12.355
The pharmacokinetic parameter of table 6 capsule formulation
The numbering maximum plasma concentration reaches the dense half-life (T in blood medicine peak
1/2) area under curve
(C
MAX) μ spends time H (AUC
0-t1/2)
g/ml (T
MAX)H μg/ml*H
1 4.89 0.46 6.35 21.602
2 4.75 0.42 6.12 20.306
3 5.04 0.50 6.38 21.697
4 4.92 0.42 6.22 21.402
5 5.14 0.48 6.18 21.973
The result shows: soft capsule preparation of the present invention is compared tangible absorption of capsule preparations and is speeded (time that arrives peak concentration shortens), and maximum plasma concentration increases (peak concentration increase), and half-life while shortens, and the toxic component of medicine is difficult for accumulating in vivo.
Experimental example 4: flat elimination capsule antitumor action
Mice is divided into 4 groups at random, i.e. normal control group, lotus tumor model group, normal medicine feed group and lotus tumor medicine feed group.Every group of mice pressed the 20g/kg administration, every day 1 time, continuous 10 days.Normal control group and lotus tumor model group gavage isopyknic normal saline simultaneously.Every treated animal is all put to death the next day of drug withdrawal, gets spleen and does the active detection of spleen IL-2.The result shows that lotus tumor medicine feed group IL-2 activity illustrates that apparently higher than lotus tumor model group flat elimination capsule can obviously strengthen tumor mice IL-2 activity.Normal medicine feed group and normal control group no significant difference illustrate that flat elimination capsule is to the active nothing influence of normal body IL-2.
Experimental example 5: set upright and Detoxication:
Flat elimination capsule can obviously strengthen high temperature resistant, cold-resistant, the hypoxia-bearing capability of lotus S180 solid tumor mice, strengthens cellular immunization and the humoral immunity level of lotus mice, and strengthens the activity of tumor necrosis factor, illustrates that flat elimination capsule has centralizing function.Flat elimination capsule can resist bone marrow depression, granulocytopenia and the hepar damnification of mice after cyclophosphamide and the radiation treatment, illustrates that flat elimination capsule has protective effect to chemotherapy and radiocurable untoward reaction.
Embodiment
Preparation of soft capsule method of the present invention
1, extract:
(1) Radix Curcumae 50g, Fructus Aurantii 85g two flavor pulverizing medicinal materials become coarse powder, cross 24 mesh sieves; Oletum Trogopterori 45g, Alumen 58g, Sal Nitri 54g, Resina Toxicodendri 20g four Chinese medicine material is ground into fine powder, crosses 100 mesh sieves; With 8 times of amount 70% ethanol, flood after 24 hours, promptly get percolate with 5ml/min speed percolation, merge standby behind the diacolation liquid recycling ethanol;
(2) last medicinal residues behind the percolation are added 8 times of water with Herba Agrimoniae 55g, decoct three times, decocted 2 hours at every turn.Collecting decoction filters, and concentrates; In concentrated solution, add ethanol and adjust to that to contain the alcohol amount be 80%, staticly settled 24 hours, filter that to collect filter cake standby at 4 ℃～8 ℃;
(3) percolate spherical tank decompression recycling ethanol is crossed the macropore resin bed respectively after merging and pure hypostasis filter with 400 order filter clothes behind the percolate recovery ethanol and is analysed post, with ethanol and distilled water eluting; Obtain refining extract after the concentrated back of merging eluent is spray-dried.
2, adding is crossed 120 mesh sieves through the Semen Strychni Pulveratum 20g of superfine grinding mix homogeneously in the above-mentioned refining extract, under stirring, join in the PEG400 gradually, heating makes it to remain on 60 ℃ and stir and to make it dissolving, fully stirring makes it be mixed into uniform suspension, again suspension crossed pelleting behind colloid mill, the degassing evacuation, finalized the design, select ball, wash ball, drying, promptly get 1000 of flat elimination capsules.
Claims (2)
1, a kind of Chinese medicinal soft capsule preparation is characterized in that it being to be prepared from by following method:
Radix Curcumae 50～58 weight portion Herba Agrimoniaes 50～58 weight portion Fructus Aurantiis 85～95 weight portions
Oletum Trogopterori 40～50 weight portion Alumens 50～58 weight portion Sal Nitri 50～58 weight portions
Resina Toxicodendri 15～20 weight portion Semen Strychni Pulveratums 15～30 weight portions
Radix Curcumae, Fructus Aurantii two flavor pulverizing medicinal materials are become coarse powder, cross 24 orders～50 mesh sieves; Oletum Trogopterori, Alumen, Sal Nitri, Resina Toxicodendri four Chinese medicine material are ground into fine powder, cross 100 orders～120 mesh sieves; With 60～80% ethanol percolations, merge behind the diacolation liquid recycling ethanol;
The last medicinal residues of percolation are with Herba Agrimoniae decocting three times, and collecting decoction filters, and concentrates; Add ethanol and staticly settle, the collecting precipitation thing is dissolved in water;
Percolate spherical tank decompression recycling ethanol is crossed the macropore resin bed respectively after merging and pure hypostasis filter with 400 order filter clothes behind the percolate recovery ethanol and is analysed post, with ethanol and distilled water eluting; Obtain refining extract after the concentrated back of merging eluent is spray-dried;
Add in the above-mentioned refining extract and cross 80～120 mesh sieves through the Semen Strychni Pulveratum mix homogeneously of superfine grinding, under stirring, join solvent gradually, heating makes it to remain on 40～80 ℃ and stir and to make it dissolving, the dissolving back adds adjuvants such as wetting agent, suspending agent and stabilizing agent, fully stirs to make it be mixed into uniform suspension; Again suspension crossed pelleting behind colloid mill, the degassing evacuation, finalized the design, select ball, wash ball, drying, promptly.
2, a kind of according to claim 1 Chinese medicinal soft capsule preparation is characterized in that it being to be prepared from by following method:
Radix Curcumae 54 weight portion Herba Agrimoniaes 55 weight portion Fructus Aurantiis 80 weight portion Oletum Trogopteroris 45 weight portions
Alumen 58 weight portion Sal Nitri 54 weight portion Resina Toxicodendri 20 weight portion Semen Strychni Pulveratums 20 weight portions
Radix Curcumae, Fructus Aurantii two flavor pulverizing medicinal materials are become coarse powder, cross 24 mesh sieves; Oletum Trogopterori, Alumen, Sal Nitri, Resina Toxicodendri four Chinese medicine material are ground into fine powder, cross 100 mesh sieves; With 8 times of amount 70% ethanol, flood after 24 hours, promptly get percolate with 5ml/min speed percolation, merge standby behind the diacolation liquid recycling ethanol;
The last medicinal residues of percolation add 8 times of water with Herba Agrimoniae, and decocting three times decocted 2 hours at every turn, and collecting decoction filters, and concentrates; Add ethanol and adjust to that to contain the alcohol amount be 80%, staticly settled 24 hours at 4 ℃～8 ℃, the collecting precipitation thing is dissolved in water;
Percolate spherical tank decompression recycling ethanol is crossed the macropore resin bed respectively after merging and pure hypostasis filter with 400 order filter clothes behind the percolate recovery ethanol and is analysed post, with ethanol and distilled water eluting; Obtain refining extract after the concentrated back of merging eluent is spray-dried;
Add in the above-mentioned refining extract and cross 120 mesh sieves through the Semen Strychni Pulveratum mix homogeneously of superfine grinding, under stirring, join in the PEG400 gradually, heating makes it to remain on 60 ℃ and stir and to make it dissolving, fully stirring makes it be mixed into uniform suspension, again suspension crossed pelleting behind colloid mill, the degassing evacuation, finalized the design, select ball, wash ball, drying, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100374097A CN1268324C (en) | 2004-04-30 | 2004-04-30 | Chinese medicinal soft capsule and preparing process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100374097A CN1268324C (en) | 2004-04-30 | 2004-04-30 | Chinese medicinal soft capsule and preparing process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1569197A true CN1569197A (en) | 2005-01-26 |
| CN1268324C CN1268324C (en) | 2006-08-09 |
Family
ID=34481657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100374097A Expired - Lifetime CN1268324C (en) | 2004-04-30 | 2004-04-30 | Chinese medicinal soft capsule and preparing process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1268324C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574506B (en) * | 2008-05-29 | 2010-12-29 | 宁夏金太阳药业有限公司 | Method for preparing pingxiao preparation |
| CN102499960A (en) * | 2011-11-29 | 2012-06-20 | 上海景峰制药有限公司 | Method for improving uniformity of strychnine in nux vomica powder of bone and tendon pill capsules |
| CN103566281A (en) * | 2012-07-27 | 2014-02-12 | 西安正大制药有限公司 | Traditional Chinese medicine composition with anti-tumor effect and preparation method thereof |
| CN103566282A (en) * | 2012-07-27 | 2014-02-12 | 西安正大制药有限公司 | Traditional Chinese medicine composition with anti-tumor effect and preparation method thereof |
-
2004
- 2004-04-30 CN CNB2004100374097A patent/CN1268324C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574506B (en) * | 2008-05-29 | 2010-12-29 | 宁夏金太阳药业有限公司 | Method for preparing pingxiao preparation |
| CN102499960A (en) * | 2011-11-29 | 2012-06-20 | 上海景峰制药有限公司 | Method for improving uniformity of strychnine in nux vomica powder of bone and tendon pill capsules |
| CN103566281A (en) * | 2012-07-27 | 2014-02-12 | 西安正大制药有限公司 | Traditional Chinese medicine composition with anti-tumor effect and preparation method thereof |
| CN103566282A (en) * | 2012-07-27 | 2014-02-12 | 西安正大制药有限公司 | Traditional Chinese medicine composition with anti-tumor effect and preparation method thereof |
| CN103566281B (en) * | 2012-07-27 | 2016-12-21 | 西安正大制药有限公司 | A kind of Traditional Chinese medicine composition with anti-tumor effect and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1268324C (en) | 2006-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101057925A (en) | Preparation technology for 'jieguqili' capsule and its quality control method | |
| CN1748783A (en) | Dismenorrhea preparation and new preparing method | |
| CN1895462A (en) | Nankang soft capsule for treating prostatitis | |
| CN1824101A (en) | Xingsuerchen medicinal preparation and its new preparation method | |
| CN1768800A (en) | Chinese medicinal formulation for treating blennorrhagia and urinary system infection, and preparation method thereof | |
| CN1268324C (en) | Chinese medicinal soft capsule and preparing process thereof | |
| CN1931255A (en) | Medicine for treating thrombocytopenia and anemia and its prepn process and quality control method | |
| CN1369306A (en) | 'Huajuhong' preparation and its preparing process | |
| CN1879799A (en) | Menstruation-regulating preparation with asiabell and cassia bark and method for preparing same | |
| CN1876097A (en) | Improved Chinese medicinal capsule for treating climacteric syndrome | |
| CN100350899C (en) | Diphase capsule of red sage root for coronary heart disease and preparation method | |
| CN1823982A (en) | Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method | |
| CN1772266A (en) | Compound anticancer Chinese medicine prepn and its prepn process | |
| CN1824078A (en) | Green biota body cleaning effervescent particle preparation | |
| CN1943694A (en) | A Chinese traditional medicinal composition for treating renal deficiency, edema, lumbago and gonalgia, etc. | |
| CN1775258A (en) | Womb-warming pregnancy-aiding preparation and new preparing method | |
| CN1304045C (en) | Arthralgia removing pills and their preparation | |
| CN1067256C (en) | Concentrated chinese medicine preparation and its preparation process | |
| CN1718578A (en) | Lerivisiticum extract, its preparation method and medicine containing said extract | |
| CN1748775A (en) | Nujin preparation and new preparing method | |
| CN1456198A (en) | Angong hemostatics | |
| CN1679869A (en) | Preparation for diabetes and its making method | |
| CN1742798A (en) | Wuhaiyingliu preparation and new preparing method | |
| CN1879777A (en) | Blood circulation-invigorating tendon-strengthening preparation and method for preparing same | |
| CN1543968A (en) | Drug prepared by mulberry bark extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: GANSU DUYIWEI BIOLOGY PHARMACY CO., LTD. Free format text: FORMER NAME OR ADDRESS: GANSU DUYIWEI BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 610041, 11FA-C, Asia Pacific Plaza, 58 KELONG Road North, Sichuan, Chengdu Patentee after: GANSU DUYIWEI BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Address before: 610041, 11FA-C, Asia Pacific Plaza, 58 KELONG Road North, Sichuan, Chengdu Patentee before: Gansu Duyiwei Biological Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: HENGKANG MEDICAL GROUP CO., LTD. Free format text: FORMER NAME: GANSU DUYIWEI BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 610041, 11FA-C, Asia Pacific Plaza, 58 KELONG Road North, Sichuan, Chengdu Patentee after: HENGKANG MEDICAL GROUP CO.,LTD. Address before: 610041, 11FA-C, Asia Pacific Plaza, 58 KELONG Road North, Sichuan, Chengdu Patentee before: GANSU DUYIWEI BIOLOGICAL PHARMACEUTICAL Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 746500 Gansu city of Longnan Province Wang Kang dam Duyiwei Industrial Park Patentee after: HENGKANG MEDICAL GROUP CO.,LTD. Address before: 610041, 11FA-C, Asia Pacific Plaza, 58 KELONG Road North, Sichuan, Chengdu Patentee before: HENGKANG MEDICAL GROUP CO.,LTD. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181106 Address after: 746500 Wang Yi Industrial Park, Wang Ba, Kang County, Longnan, Gansu Patentee after: KANGXIAN DUYIWEI BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Address before: 746500 Wang Yi Industrial Park, Wang Ba, Kang County, Longnan, Gansu Patentee before: HENGKANG MEDICAL GROUP CO.,LTD. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A soft capsule preparation of traditional Chinese medicine and its preparation technology Effective date of registration: 20210201 Granted publication date: 20060809 Pledgee: Kangxian sub branch of industrial and Commercial Bank of China Ltd. Pledgor: KANGXIAN DUYIWEI BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Registration number: Y2021620000002 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230306 Granted publication date: 20060809 Pledgee: Kangxian sub branch of industrial and Commercial Bank of China Ltd. Pledgor: KANGXIAN DUYIWEI BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Registration number: Y2021620000002 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Traditional Chinese Medicine Soft Capsule Preparation and Its Preparation Process Effective date of registration: 20230614 Granted publication date: 20060809 Pledgee: Kangxian sub branch of industrial and Commercial Bank of China Ltd. Pledgor: KANGXIAN DUYIWEI BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Registration number: Y2023620000016 |